Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acrylic Acid SCHEMBL11799648 | 0.87 | LMNA (0.53) | LMNAALDH1A1TSHRHTTALOX15 | |
| Acrylic Acid SCHEMBL10979925 | 0.86 | LMNA (0.42) | LMNAALDH1A1TSHRALOX15HSD17B10 | |
| Acrylonitrile SCHEMBL8915523 | 0.84 | ALDH1A1 (0.36) | ALDH1A1TSHR | |
| Methacrylic Acid SCHEMBL9168052 | 0.81 | LMNA (0.46) | LMNAALDH1A1TSHRALOX15HSD17B10 | |
| Acrylic Acid SCHEMBL305585 | 0.80 | LMNA (0.62) | LMNAALDH1A1TSHRALOX15HSD17B10 | |
| Acrylic Acid SCHEMBL99589 | 0.80 | — | — | |
| Acrylonitrile SCHEMBL1885744 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TSHR | |
| Acrylonitrile SCHEMBL28978 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TSHR | |
| SCHEMBL8440673 | 0.78 | HTT (0.39) | LMNAALDH1A1TSHRHTTKMT2A | |
| Butadiene SCHEMBL27092731 | 0.78 | HTT (0.39) | LMNAALDH1A1TSHRHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999718-B2 | Pyrazole derivatives | APTABIO THERAPEUTICS INC. (KR) | 2024-06-04 | — | — | US | disclosed |
| US-20230234940-A1 | NOVEL PYRAZOLE DERIVATIVES | APTABIO THERAPEUTICS INC. (KR) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999718-B2 | Pyrazole derivatives | CYP11B1, CYP11B2, CYP3A43 | LMNA 4473/4885ALDH1A1 728/4885TSHR 2023/4885 |
| US-20230234940-A1 | NOVEL PYRAZOLE DERIVATIVES | CYP4B1, CYP3A43, CYP11B1 | LMNA 4438/4885ALDH1A1 633/4885TSHR 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.